A new survey from BBK Worldwide (BBK), challenges the long-held notion that physicians are not willing to refer their patients to other specialists for access to clinical studies. The latest “Study Voices” survey - part of an ongoing series of surveys designed to shed light on key clinical research trends - features perspectives from pharmaceutical and biotechnology sponsors, physicians, and patients. The patient portion was conducted as part of BBK’s partnership with Health Union, a pioneer in online communities for people with chronic health conditions.
With more than two-thirds of physicians surveyed indicating they have referred a patient to a clinical study, and half of the sponsors surveyed assuming the exact opposite, the findings underscore the need for sponsor awareness and support for concentrated efforts to engage potential referring physicians during the recruitment stage of a clinical study.
Survey findings revealed that 53 percent of sponsors believe that doctors are unwilling to refer their patients to other specialists for access to clinical trials, while 69 percent of doctors said they had in fact referred a patient. The survey also challenged the notion that doctors are reluctant to refer because of concerns over losing the patient or losing revenue. In fact, 68 percent of doctors surveyed said the reason they did not refer a patient was because of lack of information about the protocol - only 9 percent were concerned about losing the patient or losing revenue.
Findings from members of Health Union’s online communities revealed that the majority of patients learned about a clinical study opportunity from their doctor - 35 percent of whom were referred to a different doctor conducting the clinical study. Among those that were not referred, 71 percent said they would still have wanted to participate if they had been referred to a different doctor. Lastly, of those that had been referred to a specialist for care in the clinical trial, 79 percent returned to their regular doctor for continued treatment and 11 percent continued to see both the study doctor and their regular doctor following the conclusion of the study. “Compelling on their own, the findings also allude to the importance of the physician-patient relationship. It seems that the better the relationship is – with more open lines of communication – the more likely the doctor will introduce clinical research as an option and the more likely the patient will participate,” said Matt Kibby, Principal and President, BBK Worldwide.
“This survey confirms what we see every day via interactions within our condition-specific online communities: many people with chronic health concerns are eager to learn about clinical trials, and healthcare providers are important influencers in patients’ decisions to participate in clinical research,” said Olivier Chateau, Co-Founder and CEO, Health Union.
“The fact that more than a third of patients participating in clinical studies were referrals not only dispels the notion that doctors don’t refer, but it also suggests there may be room to increase that number,” said Kibby. “We just need to encourage doctors to continue to think about clinical research as part of the ecosystem of options for the patient’s healthcare.”
The Study Voices survey includes responses from 655 patients, 131 physicians, and 194 study sponsors, and it was conducted between April and June 2019.
Learn more at www.bbkworldwide.com
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.